Selonterra

Selonterra is a private, pre-revenue biotech startup pioneering a novel approach to neurodegenerative diseases. The company's platform integrates human genetics with gene expression network analysis to identify unexploited, druggable targets, with initial programs targeting Alzheimer's (APOE4) and Parkinson's disease (SNCA, LRRK2). Led by a team of experienced industry veterans, the company is advancing its lead small molecule compounds through lead optimization towards IND-enabling studies. Selonterra aims to develop accessible, convenient oral therapies that address the root causes of these devastating conditions.

A proprietary platform that integrates human genetics with gene expression network analysis to identify novel, unexploited, and druggable targets for neurodegenerative diseases. It focuses on key mediators dysregulated by genetic risk factors to develop small molecule modulators.

Selonterra operates in the highly competitive neurodegeneration space, competing with large pharmaceutical companies (e.g., Biogen, Eli Lilly, Roche) and numerous biotechs pursuing amyloid, tau, alpha-synuclein, inflammation, and other mechanisms. Its key differentiation is its focus on novel targets derived from an integrated genetics and network biology platform, a space also explored by companies like Denali Therapeutics. Its small molecule modality offers a potential advantage in convenience over biologic approaches.